PMV Pharma Posts $34.4M Q3 Loss as Cash Runway Tightens
PMVP sits 23% above its 52-week low of $1.02 on light trading volume (0.3× avg).
Summary
PMV Pharmaceuticals reported a $34.4 million third-quarter loss, a sharp widening from the $18.09 million net loss it posted in Q2, with the loss per share at 52 cents and research and development expenses of $16.1 million. The company entered the quarter with a going-concern warning and a $79.4 million cash balance as of the June 30 10-Q, so a loss of this size consumes a large share of remaining liquidity; it reported $108.5 million in cash and $52.4 million in nine-month operating cash use. It follows the $50.8 million offering priced September 1 at $1.21 per share with warrants, which was already a steep discount to the prior price. With the stock at $1.26 and a micro-cap valuation, dilution risk and runway are the dominant issues for holders.
At the time of this announcement, PMVP was trading at $1.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $94.4M. The 52-week trading range was $1.02 to $1.91. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.